What It Is
A dual GIP/GLP-1 agonist.
Tirzepatide is the active ingredient in Mounjaro and Zepbound, acting on two metabolic pathways at once.
Provider-supervised tirzepatide, a dual GIP/GLP-1 therapy — guided by labs, not a fixed protocol.
Not sure if tirzepatide or semaglutide is the right fit? Take the 60-second fit quiz.
Quick take
Tirzepatide is the active ingredient in Mounjaro and Zepbound, acting on two metabolic pathways at once.
At Revi, tirzepatide is paired with labs, nutrition strategy, and monitoring — not prescribed as a standalone shortcut.
Thyroid, metabolic, and relevant health markers are reviewed before your provider confirms it's the right fit.
Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. It's the active ingredient in the FDA-approved medications Mounjaro and Zepbound. Because it acts on two metabolic pathways instead of one, some patients see a different response profile than with semaglutide alone. For patients in Lincoln, NE, tirzepatide is often considered when a broader metabolic approach is appropriate.
At Revi, tirzepatide isn't treated as a shortcut. We pair it with lab-based assessment of the underlying drivers — thyroid, hormones, metabolic function, inflammation — and ongoing monitoring, because appetite regulation is only part of a durable plan.
Tirzepatide is typically started at a low dose and titrated upward over a period of weeks to months, under provider supervision, based on your response and tolerability. This gradual approach is standard practice and is designed to minimize side effects while your body adjusts.
Your exact schedule is set by your provider based on labs, history, and how you respond — not a fixed timeline. Individual results vary.
Nausea, mild digestive changes, and appetite suppression are the most commonly reported effects, especially during dose increases. Your provider monitors for these at each check-in and adjusts your plan accordingly. Bring your full medication list and medical history to your consultation so contraindications can be reviewed before treatment starts.
FDA-approved branded tirzepatide options are reviewed first. If a compounded option is discussed, your provider will explain the current regulatory status, whether it is legally and clinically appropriate for your case, and how pharmacy availability affects the plan.
Tirzepatide acts on two metabolic pathways (GIP and GLP-1); semaglutide acts on one (GLP-1). Neither is universally "better" — the right choice depends on your labs, history, prior response to GLP-1 therapy, and goals. See our Semaglutide in Lincoln, NE page for a full comparison, or take the 60-second fit quiz to get pointed in the right direction before you book.
We discuss the specifics during your consultation. FDA-approved branded options are reviewed first. If a compounded option is discussed, your provider will explain the current regulatory status, whether it is legally and clinically appropriate for your case, and how availability affects the plan.
Semaglutide acts on one metabolic pathway (GLP-1). Tirzepatide acts on two (GIP and GLP-1). Neither is universally better — the right choice depends on your labs, history, prior GLP-1 response, and goals.
Tirzepatide is typically started at a low dose and titrated upward over several weeks to months under provider supervision, based on response and tolerability.
Nausea, mild digestive changes, and appetite suppression are the most commonly reported effects, especially during dose increases. Your provider monitors for these and adjusts your plan accordingly.
Yes. Revi reviews thyroid, metabolic, insulin, and relevant health markers before starting any GLP-1/GIP therapy to confirm it's an appropriate fit and to rule out contraindications.
Owner and Medical Director. Board-certified interventional radiologist with 20+ years of experience.
Read full bio →